Login
Companies $TNDM
$18.80 +$0.32 (1.73%) After hours
TANDEM DIABETES CARE INC logo

TANDEM DIABETES CARE INC

tandemdiabetes.com

What Do They Do?

Sells insulin pumps and replacement supplies, and offers diabetes data tools for people with diabetes, caregivers and healthcare providers.

How Do They Make Money?

Supplies and other products are the largest sales stream; people with third-party insurance and distributors buy these products and pumps. Sales count when products ship to distributors or reach direct customers; software access and support is spread over the pump warranty period.

revenue
SegmentShareRevenue
Pump
Sold outright

46%
FY2022: 54%
Supplies and other
Sold outright

54%
FY2022: 47%
Net sales recognized (deferred) for Tandem Choice program
0.0%
FY2022: −0.4%

Who Are Their Customers?

People with diabetes buy pumps and supplies through U.S. and international distribution partners; in the U.S. and Canada, Tandem also sells directly, with distributors handling some order fulfillment.

Do Revenues Turn Into Profits?

No. It lost $204.7M in FY2025.

Operating income, FY2025
−18% of revenue
▼ −89% (Loss) vs FY2024 (−$99.1M, −11%)
Net income, FY2025
−20% of revenue
▼ −113% (Loss) vs FY2024 (−$96M, −10%)
Free cash flow, FY2025
−3% of revenue
▼ Turned to a loss vs FY2024 ($5M, 1%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +14%
vs $249.3M in Q3 FY2025
Net income
▲ +67% (Loss)
vs −$21.2M in Q3 FY2025
Supplies and other share of revenue vs 55.8% in Q3 FY2025
  • Nov 12, 2026 FDA clears a tubeless Tandem Mobi insulin delivery option A new cartridge and infusion set can convert Mobi to tubeless use; U.S. commercial launch is planned for the first half of 2027.
  • Nov 5, 2026 Reaffirms 2026 financial guidance Sales are estimated at $1.065 billion to $1.085 billion; gross margin at 56% to 57% and adjusted EBITDA margin at 5% to 6%.

Growing. Revenue grew 44% in 4 years, from $702.8M in FY2021 to $1B in FY2025, about 10% a year.

Broader pump lineup Earlier commercial efforts focused exclusively on the flagship pump; the latest report describes a wider pump portfolio that includes Mobi.

Revenue over time
Pump Supplies and other Net sales recognized (deferred) for Tandem Choice program
$2B$1B$0

Who Do They Compete With?

Competes with Beta Bionics, Insulet, Medtronic, mylife, and Sequel

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support